BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer. JCO 2010;28:3239-47. [DOI: 10.1200/jco.2008.21.6457] [Cited by in Crossref: 635] [Cited by in F6Publishing: 259] [Article Influence: 57.7] [Reference Citation Analysis]
Number Citing Articles
1 Preusser M, Fülöp G, Berghoff AS, Heinzl H, Steger GG, Greil R, Zielinski CC, Bartsch R. Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer. Oncologist. 2012;17:e13-e17. [PMID: 22744818 DOI: 10.1634/theoncologist.2012-0115] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
2 Higgins MJ, Baselga J. Breast cancer in 2010: Novel targets and therapies for a personalized approach. Nat Rev Clin Oncol. 2011;8:65-66. [PMID: 21278769 DOI: 10.1038/nrclinonc.2010.217] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
3 Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol 2018;25:S142-50. [PMID: 29910657 DOI: 10.3747/co.25.3954] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 34.7] [Reference Citation Analysis]
4 Maeda H, Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs. Clin Transl Med 2018;7:11. [PMID: 29541939 DOI: 10.1186/s40169-018-0185-6] [Cited by in Crossref: 132] [Cited by in F6Publishing: 107] [Article Influence: 44.0] [Reference Citation Analysis]
5 Mendiola M, Martínez-Marin V, Herranz J, Heredia V, Yébenes L, Zamora P, Castelo B, Pinto Á, Miguel M, Díaz E, Gámez A, Fresno JÁ, Ramírez de Molina A, Hardisson D, Espinosa E, Redondo A. Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel. Oncotarget 2016;7:24217-27. [PMID: 26992213 DOI: 10.18632/oncotarget.8128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. Med Care 2013;51:622-7. [PMID: 23604014 DOI: 10.1097/MLR.0b013e318290216f] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
7 Gomez P, Lacouture ME. Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 2011;16:1508-19. [PMID: 22016478 DOI: 10.1634/theoncologist.2011-0115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
8 Welt A, Marschner N, Lerchenmueller C, Decker T, Steffens CC, Koehler A, Depenbusch R, Busies S, Hegewisch-Becker S. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial. Breast Cancer Res Treat 2016;156:97-107. [PMID: 26927446 DOI: 10.1007/s10549-016-3727-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
9 Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, Greil R. DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer. Theranostics 2018;8:2278-88. [PMID: 29721079 DOI: 10.7150/thno.23544] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
10 Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol 2013;24:66-82. [PMID: 23346316 DOI: 10.3802/jgo.2013.24.1.66] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
11 Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ 2017;359:j4530. [PMID: 28978555 DOI: 10.1136/bmj.j4530] [Cited by in Crossref: 268] [Cited by in F6Publishing: 184] [Article Influence: 67.0] [Reference Citation Analysis]
12 Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo 2020;34:1377-86. [PMID: 32354934 DOI: 10.21873/invivo.11917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Li Z, Qiu Y, Lu W, Jiang Y, Wang J. Immunotherapeutic interventions of Triple Negative Breast Cancer. J Transl Med 2018;16:147. [PMID: 29848327 DOI: 10.1186/s12967-018-1514-7] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
14 Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW. Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100. Br J Cancer 2014;111:1241-8. [PMID: 25117820 DOI: 10.1038/bjc.2014.430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
15 Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, Magnusson NE. Anti-vascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014;15:23024-41. [PMID: 25514409 DOI: 10.3390/ijms151223024] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
16 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
17 Croom KF, Dhillon S. Bevacizumab: a review of its use in combination with paclitaxel or capecitabine as first-line therapy for HER2-negative metastatic breast cancer. Drugs 2011;71:2213-29. [PMID: 22035518 DOI: 10.2165/11207720-000000000-00000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
18 Miyagawa Y, Yanai A, Yanagawa T, Inatome J, Egawa C, Nishimukai A, Takamoto K, Morimoto T, Kikawa Y, Suwa H, Taji T, Yamaguchi A, Okada Y, Sata A, Fukui R, Bun A, Ozawa H, Higuchi T, Fujimoto Y, Imamura M, Miyoshi Y. Baseline neutrophil-to-lymphocyte ratio and c-reactive protein predict efficacy of treatment with bevacizumab plus paclitaxel for locally advanced or metastatic breast cancer. Oncotarget 2020;11:86-98. [PMID: 32002126 DOI: 10.18632/oncotarget.27423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Chacón López-Muñiz JI, de la Cruz Merino L, Gavilá Gregori J, Martínez Dueñas E, Oliveira M, Seguí Palmer MA, Álvarez López I, Antolin Novoa S, Bellet Ezquerra M, López-Tarruella Cobo S. SEOM clinical guidelines in advanced and recurrent breast cancer (2018). Clin Transl Oncol 2019;21:31-45. [PMID: 30617924 DOI: 10.1007/s12094-018-02010-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Obeid E, Nanda R, Fu YX, Olopade OI. The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol. 2013;43:5-12. [PMID: 23673510 DOI: 10.3892/ijo.2013.1938] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 14.5] [Reference Citation Analysis]
21 Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, Su S, Wang Q, Jin L, Wang Y, Lau WY, Jiang Z, Song E. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer 2020;8:e000696. [PMID: 32448804 DOI: 10.1136/jitc-2020-000696] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
22 Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B. A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs 2014;32:1285-94. [PMID: 24894652 DOI: 10.1007/s10637-014-0122-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
23 De Boer RH, Kotasek D, White S, Koczwara B, Mainwaring P, Chan A, Melara R, Ye Y, Adewoye AH, Sikorski R, Kaufman PA. Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat 2012;135:241-52. [PMID: 22872523 DOI: 10.1007/s10549-012-2135-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
24 Guirgis HM. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation? J Oncol Pract 2012;8:224-30. [PMID: 23180986 DOI: 10.1200/JOP.2011.000390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
25 Chen DR, Lin C, Wang YF. Window of opportunity: A new insight into sequential bevacizumab and paclitaxel in two cases of metastatic triple-negative breast cancer. Exp Ther Med 2015;10:885-8. [PMID: 26622409 DOI: 10.3892/etm.2015.2586] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Tong CWS, Wu M, Cho WCS, To KKW. Recent Advances in the Treatment of Breast Cancer. Front Oncol 2018;8:227. [PMID: 29963498 DOI: 10.3389/fonc.2018.00227] [Cited by in Crossref: 128] [Cited by in F6Publishing: 106] [Article Influence: 42.7] [Reference Citation Analysis]
27 Zeichner SB, Terawaki H, Gogineni K. A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer. Breast Cancer (Auckl) 2016;10:25-36. [PMID: 27042088 DOI: 10.4137/BCBCR.S32783] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
28 Rinnerthaler G, Gampenrieder SP, Hackl H, Steiner M, Monzo-Fuentes C, Melchardt T, Magnes T, Huemer F, Westphal T, Hufnagl C, Hauser-Kronberger C, Egle A, Greil R. Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial. J Clin Med 2020;9:E1663. [PMID: 32492882 DOI: 10.3390/jcm9061663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
29 Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol 2014;31:276. [PMID: 25294426 DOI: 10.1007/s12032-014-0276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Manso L, Moreno F, Márquez R, Castelo B, Arcediano A, Arroyo M, Ballesteros AI, Calvo I, Echarri MJ, Enrech S, Gómez A, González Del Val R, López-Miranda E, Martín-Angulo M, Martínez-Jañez N, Olier C, Zamora P. Use of bevacizumab as a first-line treatment for metastatic breast cancer. Curr Oncol 2015;22:e51-60. [PMID: 25908921 DOI: 10.3747/co.22.2210] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
31 Palumbo R, Sottotetti F, Trifirò G, Piazza E, Ferzi A, Gambaro A, Spinapolice EG, Pozzi E, Tagliaferri B, Teragni C, Bernardo A. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Devel Ther 2015;9:2189-99. [PMID: 25931813 DOI: 10.2147/DDDT.S79563] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
32 Beck JT. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer. Onco Targets Ther 2015;8:3629-38. [PMID: 26675495 DOI: 10.2147/OTT.S88037] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
33 Gavilá J, Lopez-Tarruella S, Saura C, Muñoz M, Oliveira M, De la Cruz-Merino L, Morales S, Alvarez I, Virizuela JA, Martin M. SEOM clinical guidelines in metastatic breast cancer 2015. Clin Transl Oncol 2015;17:946-55. [PMID: 26683474 DOI: 10.1007/s12094-015-1476-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
34 Chakrabarti A, Verbridge S, Stroock AD, Fischbach C, Varner JD. Multiscale models of breast cancer progression. Ann Biomed Eng 2012;40:2488-500. [PMID: 23008097 DOI: 10.1007/s10439-012-0655-8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
35 Li C, Xiang A, Chen X, Yin K, Lu J, Yin W. Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials. Onco Targets Ther 2017;10:3155-68. [PMID: 28721065 DOI: 10.2147/OTT.S138600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Nienhüser H, Schmidt T. Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. Int J Mol Sci 2017;19:E43. [PMID: 29295534 DOI: 10.3390/ijms19010043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
37 Wei J, Luo Y, Fu D. Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials. Onco Targets Ther 2018;11:9049-59. [PMID: 30588017 DOI: 10.2147/OTT.S186816] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
39 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 82] [Article Influence: 17.7] [Reference Citation Analysis]
40 Inagaki M, Shinohara Y, Kaburagi T, Homma S, Hizawa N, Nakamura H, Hayashihara K, Saito T, Ishikawa H, Ichimura H, Nawa T, Kikuchi N, Miyazaki K, Kodama T, Kamiyama K, Satoh H, Furukawa K. Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group. Mol Clin Oncol 2016;4:425-8. [PMID: 26998297 DOI: 10.3892/mco.2015.720] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
42 Hardy-Bessard AC, Brocard F, Clatot F, Lortholary A, You B, Grenier J, Martin-Babau J, Lucas B, Meunier J, Ferrero JM, Savoye AM, Marti A, Despax R, Moullet I, Emile G. First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study. Breast 2020;54:256-63. [PMID: 33188992 DOI: 10.1016/j.breast.2020.09.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
43 Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mælandsmo GM, Engebraaten O. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res 2014;20:404-12. [PMID: 24192926 DOI: 10.1158/1078-0432.CCR-13-1865] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
44 Barnes SL, Whisenant JG, Loveless ME, Yankeelov TE. Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics. 2012;4:442-478. [PMID: 23105959 DOI: 10.3390/pharmaceutics4030442] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
45 Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol 2012;13:e427-36. [PMID: 23026828 DOI: 10.1016/S1470-2045(12)70275-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
46 Tsai WC, Chang KM, Kao KJ. Dynamic Contrast Enhanced MRI and Intravoxel Incoherent Motion to Identify Molecular Subtypes of Breast Cancer with Different Vascular Normalization Gene Expression. Korean J Radiol 2021;22:1021-33. [PMID: 34047501 DOI: 10.3348/kjr.2020.0760] [Reference Citation Analysis]
47 Sethi N, Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 2011;11:735-48. [PMID: 21941285 DOI: 10.1038/nrc3125] [Cited by in Crossref: 253] [Cited by in F6Publishing: 231] [Article Influence: 25.3] [Reference Citation Analysis]
48 Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, Dunkel IJ, Lacouture ME. Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist 2012;17:274-8. [PMID: 22282905 DOI: 10.1634/theoncologist.2011-0198] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
49 Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, Villanueva C, Melisko M, McHenry MB, Liu D, Lee F, Pivot X. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 2013;139:411-9. [PMID: 23649189 DOI: 10.1007/s10549-013-2552-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
50 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
51 Gamucci T, Mentuccia L, Natoli C, Sperduti I, Cassano A, Michelotti A, Di Lauro L, Sergi D, Fabi A, Sarobba MG, Marchetti P, Barba M, Magnolfi E, Maugeri-Saccà M, Rossi E, Sini V, Grassadonia A, Pellegrini D, Astone A, Nisticò C, Angelini F, Vaccaro A, Pellegrino A, De Angelis C, Palleschi M, Moscetti L, Bertolini I, Buglioni S, Giordano A, Pizzuti L, Vici P. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. J Cell Physiol 2017;232:1571-8. [PMID: 27861874 DOI: 10.1002/jcp.25685] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
52 Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol 2015;10:189-98. [PMID: 25185646 DOI: 10.1007/s11523-014-0334-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
53 Rossari JR, Metzger-Filho O, Paesmans M, Saini KS, Gennari A, de Azambuja E, Piccart-Gebhart M. Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence. J Oncol 2012;2012:417673. [PMID: 23008712 DOI: 10.1155/2012/417673] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
54 Baselga J, Zamagni C, Gómez P, Bermejo B, Nagai SE, Melichar B, Chan A, Mángel L, Bergh J, Costa F, Gómez HL, Gradishar WJ, Hudis CA, Rapoport BL, Roché H, Maeda P, Huang L, Meinhardt G, Zhang J, Schwartzberg LS. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. Clin Breast Cancer 2017;17:585-594.e4. [PMID: 28830796 DOI: 10.1016/j.clbc.2017.05.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
55 Garon EB. Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. Lung Cancer 2012;77:475-81. [PMID: 22795702 DOI: 10.1016/j.lungcan.2012.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
56 Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK). SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC Cancer 2016;16:780. [PMID: 27724870 DOI: 10.1186/s12885-016-2823-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
57 Jackson DB, Sood AK. Personalized cancer medicine--advances and socio-economic challenges. Nat Rev Clin Oncol 2011;8:735-41. [PMID: 21989071 DOI: 10.1038/nrclinonc.2011.151] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
58 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
59 Saijo N. Present status and problems on molecular targeted therapy of cancer. Cancer Res Treat 2012;44:1-10. [PMID: 22500155 DOI: 10.4143/crt.2012.44.1.1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
60 Redondo A, Martínez V, Zamora P, Castelo B, Pinto A, Cruz P, Higuera O, Mendiola M, Hardisson D, Espinosa E. Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer. Onco Targets Ther 2014;7:2175-81. [PMID: 25473300 DOI: 10.2147/OTT.S70654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
61 Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012;8:403-14. [PMID: 22515444 DOI: 10.2217/fon.12.22] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
62 Trinh XB, van Dam PA, Vermeulen PB, Van Laere SJ, Van den Eynden GG, Tjalma WA, Dirix LY. VEGF-A-independent and angiogenesis-dependent tumour growth in patients with metastatic breast cancer. Clin Transl Oncol 2011;13:805-8. [PMID: 22082645 DOI: 10.1007/s12094-011-0737-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 Vitry A, Nguyen T, Entwistle V, Roughead E. Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study. J Pharm Policy Pract 2015;8:25. [PMID: 26483954 DOI: 10.1186/s40545-015-0046-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
64 Hulin JA, Gubareva EA, Jarzebska N, Rodionov RN, Mangoni AA, Tommasi S. Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer. Front Oncol 2019;9:1455. [PMID: 31993367 DOI: 10.3389/fonc.2019.01455] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
65 Su JC, Mar AC, Wu SH, Tai WT, Chu PY, Wu CY, Tseng LM, Lee TC, Chen KF, Liu CY, Chiu HC, Shiau CW. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis. Sci Rep 2016;6:28888. [PMID: 27364975 DOI: 10.1038/srep28888] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
66 Adler MJ, Dimitrov DS. Therapeutic antibodies against cancer. Hematol Oncol Clin North Am 2012;26:447-81, vii. [PMID: 22520975 DOI: 10.1016/j.hoc.2012.02.013] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
67 Yang SX, Steinberg SM, Nguyen D, Swain SM. p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer. Int J Oncol 2011;38:1445-52. [PMID: 21399868 DOI: 10.3892/ijo.2011.966] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
68 Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE. Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2014;32:3307-29. [PMID: 25185096 DOI: 10.1200/JCO.2014.56.7479] [Cited by in Crossref: 147] [Cited by in F6Publishing: 73] [Article Influence: 21.0] [Reference Citation Analysis]
69 Bender RJ, Mac Gabhann F. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One. 2013;8:e61788. [PMID: 23667446 DOI: 10.1371/journal.pone.0061788] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
70 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111. [PMID: 23208836 DOI: 10.1002/phar.1147] [Cited by in Crossref: 120] [Cited by in F6Publishing: 89] [Article Influence: 15.0] [Reference Citation Analysis]
71 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
72 Hey SP, Gyawali B, D'Andrea E, Kanagaraj M, Franklin JM, Kesselheim AS. A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises. J Natl Cancer Inst 2020;112:335-42. [PMID: 31651981 DOI: 10.1093/jnci/djz211] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
73 Swami U, Chaudhary I, Ghalib MH, Goel S. Eribulin -- a review of preclinical and clinical studies. Crit Rev Oncol Hematol 2012;81:163-84. [PMID: 21493087 DOI: 10.1016/j.critrevonc.2011.03.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
74 Chung TK, Warram J, Day KE, Hartman Y, Rosenthal EL. Time-dependent pretreatment with bevacuzimab increases tumor specific uptake of cetuximab in preclinical oral cavity cancer studies. Cancer Biol Ther 2015;16:790-8. [PMID: 25719497 DOI: 10.1080/15384047.2015.1016664] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
75 Frentzas S, Simoneau E, Bridgeman VL, Vermeulen PB, Foo S, Kostaras E, Nathan M, Wotherspoon A, Gao ZH, Shi Y, Van den Eynden G, Daley F, Peckitt C, Tan X, Salman A, Lazaris A, Gazinska P, Berg TJ, Eltahir Z, Ritsma L, Van Rheenen J, Khashper A, Brown G, Nystrom H, Sund M, Van Laere S, Loyer E, Dirix L, Cunningham D, Metrakos P, Reynolds AR. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med. 2016;22:1294-1302. [PMID: 27748747 DOI: 10.1038/nm.4197] [Cited by in Crossref: 187] [Cited by in F6Publishing: 168] [Article Influence: 37.4] [Reference Citation Analysis]
76 Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget 2017;8:42949-61. [PMID: 28487489 DOI: 10.18632/oncotarget.17306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
77 Minniti G, Clarke E, Lanzetta G, Osti MF, Trasimeni G, Bozzao A, Romano A, Enrici RM. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011;6:48. [PMID: 21575163 DOI: 10.1186/1748-717X-6-48] [Cited by in Crossref: 366] [Cited by in F6Publishing: 152] [Article Influence: 36.6] [Reference Citation Analysis]
78 Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci 2017;24:15. [PMID: 28219375 DOI: 10.1186/s12929-016-0311-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 10.5] [Reference Citation Analysis]
79 Rochefort P, Chabaud S, Pierga JY, Tredan O, Brain E, Bidard FC, Schiffler C, Polena H, Khalil-Mgharbel A, Vilgrain I, Bachelot T. Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival. Br J Cancer 2017;116:356-61. [PMID: 28056463 DOI: 10.1038/bjc.2016.427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
80 Ch'ng ES, Jaafar H, Tuan Sharif SE. Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective. Patholog Res Int 2011;2011:572706. [PMID: 21747968 DOI: 10.4061/2011/572706] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
81 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
82 Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 2015;16:1037-48. [PMID: 26272770 DOI: 10.1016/S1470-2045(15)00041-8] [Cited by in Crossref: 99] [Cited by in F6Publishing: 46] [Article Influence: 16.5] [Reference Citation Analysis]
83 Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D, Brodowicz T. Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer. Br J Cancer 2016;114:163-70. [PMID: 26657657 DOI: 10.1038/bjc.2015.419] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
84 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Bhat K, Sarkissyan M, Wu Y, Vadgama JV. GROα overexpression drives cell migration and invasion in triple negative breast cancer cells. Oncol Rep 2017;38:21-30. [PMID: 28560447 DOI: 10.3892/or.2017.5668] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
86 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 474] [Cited by in F6Publishing: 416] [Article Influence: 47.4] [Reference Citation Analysis]
87 Tabana Y, Okoye IS, Siraki A, Elahi S, Barakat KH. Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis. Front Oncol 2021;11:628138. [PMID: 33747948 DOI: 10.3389/fonc.2021.628138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Lee KL, Chen G, Chen TY, Kuo YC, Su YK. Effects of Cancer Stem Cells in Triple-Negative Breast Cancer and Brain Metastasis: Challenges and Solutions. Cancers (Basel) 2020;12:E2122. [PMID: 32751846 DOI: 10.3390/cancers12082122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
89 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
90 Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology 2015;4:e985940. [PMID: 25949870 DOI: 10.4161/2162402X.2014.985940] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
91 Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol 2016;34:2602-9. [PMID: 27138575 DOI: 10.1200/JCO.2015.66.1595] [Cited by in Crossref: 64] [Cited by in F6Publishing: 25] [Article Influence: 12.8] [Reference Citation Analysis]
92 Dykes SS, Hughes VS, Wiggins JM, Fasanya HO, Tanaka M, Siemann D. Stromal cells in breast cancer as a potential therapeutic target. Oncotarget 2018;9:23761-79. [PMID: 29805773 DOI: 10.18632/oncotarget.25245] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
93 Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121:3797-3803. [PMID: 21965336 DOI: 10.1172/jci57152] [Cited by in Crossref: 232] [Cited by in F6Publishing: 126] [Article Influence: 23.2] [Reference Citation Analysis]
94 Schneeweiss A, Ruckhäberle E, Huober J. Chemotherapy for Metastatic Breast Cancer - An Anachronism in the Era of Personalised and Targeted Oncological Therapy? Geburtshilfe Frauenheilkd 2015;75:574-83. [PMID: 26166838 DOI: 10.1055/s-0035-1546150] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
95 Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011;11:82-92. [PMID: 21569994 DOI: 10.1016/j.clbc.2011.03.005] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 9.2] [Reference Citation Analysis]
96 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
97 Duda DG, Munn LL, Jain RK. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst 2013;105:762-5. [PMID: 23670727 DOI: 10.1093/jnci/djt114] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
98 Shin S, Noh Y. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Ther Clin Risk Manag 2018;14:833-47. [PMID: 29765225 DOI: 10.2147/TCRM.S148840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
99 Sabatier R, Pierga JY, Curé H, Abulnaja R, Lambaudie E, Bidard FC, Extra JM, Sfumato P, Gonçalves A. Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial. Cancers (Basel) 2021;13:E140. [PMID: 33466225 DOI: 10.3390/cancers13010140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Zhu A, Yuan P, Hu N, Li M, Wang W, Wang X, Yue J, Wang J, Luo Y, Ma F, Zhang P, Li Q, Xu B, Cao S, Lippi G, Naito Y, Osman MA, Marta GN, Franceschini G, Orlandi A. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA. Cancer Biol Med 2021:j. [PMID: 34037346 DOI: 10.20892/j.issn.2095-3941.2020.0418] [Reference Citation Analysis]
101 Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol 2013;24:2548-54. [PMID: 23798616 DOI: 10.1093/annonc/mdt213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
102 Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 2014;7:1415-22. [PMID: 25143746 DOI: 10.2147/OTT.S64559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
103 Claessens AKM, Bos MEMM, Lopez-yurda M, Bouma JM, Rademaker-lakhai JM, Honkoop AH, de Graaf H, van Druten E, van Warmerdam LJC, van der Sangen MJC, Tjan-heijnen VCG, Erdkamp FLG; The Dutch Breast Cancer Research Group (BOOG). Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG). Breast Cancer Res Treat 2018;172:413-23. [DOI: 10.1007/s10549-018-4906-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
104 Reddy S, Raffin M, Kaklamani V. Targeting angiogenesis in metastatic breast cancer. Oncologist 2012;17:1014-26. [PMID: 22843553 DOI: 10.1634/theoncologist.2012-0043] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
105 Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, Gärtner F. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. ScientificWorldJournal 2014;2014:919570. [PMID: 24563633 DOI: 10.1155/2014/919570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
106 Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer 2014;110:551-5. [PMID: 24495873 DOI: 10.1038/bjc.2013.725] [Cited by in Crossref: 231] [Cited by in F6Publishing: 187] [Article Influence: 33.0] [Reference Citation Analysis]
107 Aprile G, Bonotto M, Ongaro E, Pozzo C, Giuliani F. Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use. Drugs. 2013;73:2003-2015. [PMID: 24277700 DOI: 10.1007/s40265-013-0154-8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
108 Kader YA, Spielmann M, El-Nahas T, Sakr A, Metwally H. Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer. Breast Cancer (Dove Med Press) 2013;5:37-42. [PMID: 24648756 DOI: 10.2147/BCTT.S44728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Nugue G, Bidart M, Arlotto M, Mousseau M, Berger F, Pelletier L. Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab. PLoS One. 2013;8:e72021. [PMID: 23951280 DOI: 10.1371/journal.pone.0072021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
110 Wehland M, Bauer J, Magnusson NE, Infanger M, Grimm D. Biomarkers for anti-angiogenic therapy in cancer. Int J Mol Sci 2013;14:9338-64. [PMID: 23629668 DOI: 10.3390/ijms14059338] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
111 Freyer G, Isambert N, You B, Zanetta S, Falandry C, Favier L, Trillet-Lenoir V, Assadourian S, Soussan-Lazard K, Ziti-Ljajic S, Fumoleau P. Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. Br J Cancer 2012;107:598-603. [PMID: 22790797 DOI: 10.1038/bjc.2012.304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
112 Kümmel S, Jackisch C, Müller V, Schneeweiss A, Klawitter S, Lux MP. Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit? Cancer Manag Res 2018;10:5423-31. [PMID: 30519090 DOI: 10.2147/CMAR.S177240] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
113 Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, Fujii T, Seki N, Kawahara A, Kage M, Matsueda S, Akagi Y, Yamada A, Itoh K, Sasada T. Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients. Breast Cancer Res 2014;16:R70. [PMID: 24992895 DOI: 10.1186/bcr3685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
114 Nielsen DL, Andersson M, Andersen JL, Kamby C. Antiangiogenic therapy for breast cancer. Breast Cancer Res 2010;12:209. [PMID: 21067536 DOI: 10.1186/bcr2642] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
115 Martín M, Loibl S, Hyslop T, De la Haba-Rodríguez J, Aktas B, Cirrincione CT, Mehta K, Barry WT, Morales S, Carey LA, Garcia-Saenz JA, Partridge A, Martinez-Jañez N, Hahn O, Winer E, Guerrero-Zotano A, Hudis C, Casas M, Rodriguez-Martin C, Furlanetto J, Carrasco E, Dickler MN; GEICAM Spanish Breast Cancer Group., GBG (German Breast Group)., Alliance for Clinical Trials in Oncology (Alliance). Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials. Eur J Cancer 2019;117:91-8. [PMID: 31276981 DOI: 10.1016/j.ejca.2019.06.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
116 Gonzalez-Angulo AM, Hortobagyi GN, Ellis LM. Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 2011;8:319-20. [PMID: 21556024 DOI: 10.1038/nrclinonc.2011.66] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
117 Munagala R, Aqil F, Gupta RC. Promising molecular targeted therapies in breast cancer. Indian J Pharmacol 2011;43:236-45. [PMID: 21713084 DOI: 10.4103/0253-7613.81497] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
118 Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN. Progress against solid tumors in danger: the metastatic breast cancer example. J Clin Oncol 2012;30:3444-7. [PMID: 22927522 DOI: 10.1200/JCO.2012.41.9580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
119 Castells M, Thibault B, Delord JP, Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci 2012;13:9545-71. [PMID: 22949815 DOI: 10.3390/ijms13089545] [Cited by in Crossref: 155] [Cited by in F6Publishing: 145] [Article Influence: 17.2] [Reference Citation Analysis]
120 Li T, Wang B, Wang Z, Ragaz J, Zhang J, Sun S, Cao J, Lv F, Wang L, Zhang S, Ni C, Wu Z, Xie J, Hu X. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS One 2015;10:e0133133. [PMID: 26186012 DOI: 10.1371/journal.pone.0133133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
121 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
123 Sun S, Tang L, Zhang J, Lv F, Wang Z, Wang L, Zhang Q, Zheng C, Qiu L, Jia Z, Lu Y, Liu G, Shao Z, Wang B, Hu X. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer. Int J Nanomedicine 2014;9:1443-52. [PMID: 24672237 DOI: 10.2147/IJN.S58275] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
124 Banys-Paluchowski M, Reinhardt F, Fehm T. Disseminated Tumor Cells and Dormancy in Breast Cancer Progression. Adv Exp Med Biol 2020;1220:35-43. [PMID: 32304078 DOI: 10.1007/978-3-030-35805-1_3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
125 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
126 Li Q, Yan H, Zhao P, Yang Y, Cao B. Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Sci Rep 2015;5:15746. [PMID: 26503902 DOI: 10.1038/srep15746] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
127 Tomao F, Papa A, Zaccarelli E, Rossi L, Caruso D, Minozzi M, Vici P, Frati L, Tomao S. Triple-negative breast cancer: new perspectives for targeted therapies. Onco Targets Ther 2015;8:177-93. [PMID: 25653541 DOI: 10.2147/OTT.S67673] [Cited by in Crossref: 85] [Cited by in F6Publishing: 53] [Article Influence: 14.2] [Reference Citation Analysis]
128 Kashiwagi S, Tsujio G, Asano Y, Goto W, Takada K, Takahashi K, Morisaki T, Fujita H, Takashima T, Tomita S, Ohsawa M, Hirakawa K, Ohira M. Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironment. J Transl Med 2018;16:54. [PMID: 29523158 DOI: 10.1186/s12967-018-1443-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
129 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
130 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
131 Montagna E, Bagnardi V, Cancello G, Sangalli C, Pagan E, Iorfida M, Mazza M, Mazzarol G, Dellapasqua S, Munzone E, Goldhirsch A, Colleoni M. Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial. Breast Care (Basel) 2018;13:177-81. [PMID: 30069178 DOI: 10.1159/000487630] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
132 Rajappa S, Joshi A, Doval DC, Batra U, Rajendranath R, Deo A, Biswas G, Bajpai P, Tilak TVS, Kane S, Kumar K, Kumar M, Talele AD, Devde P, Gupta A, Joshi N, Sejpal J, Bunger D, Khan M. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett 2018;16:3757-69. [PMID: 30127986 DOI: 10.3892/ol.2018.9057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
133 Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012;2012:281261. [PMID: 21876693 DOI: 10.1155/2012/281261] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
134 Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis 2020;23:55-74. [PMID: 31865479 DOI: 10.1007/s10456-019-09698-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
135 Kiso M, Tanaka S, Saji S, Toi M, Sato F. Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network. Int J Cancer 2018;143:2905-18. [PMID: 29971782 DOI: 10.1002/ijc.31645] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
136 Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res 2018;132:47-68. [PMID: 29604436 DOI: 10.1016/j.phrs.2018.03.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 13.3] [Reference Citation Analysis]
137 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biol Ther 2018;19:328-34. [PMID: 29336662 DOI: 10.1080/15384047.2017.1416938] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
139 Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Transl Oncol 2016;9:453-7. [PMID: 27751350 DOI: 10.1016/j.tranon.2016.07.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 11.8] [Reference Citation Analysis]
140 Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med 2019;9:E84. [PMID: 31905724 DOI: 10.3390/jcm9010084] [Cited by in Crossref: 69] [Cited by in F6Publishing: 50] [Article Influence: 34.5] [Reference Citation Analysis]
141 Bear HD, Tang G, Rastogi P, Geyer CE, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Ann Surg Oncol. 2017;24:1853-1860. [PMID: 27864694 DOI: 10.1245/s10434-016-5662-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
142 Craft JM, Hallahan D. Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy. Future Med Chem 2011;3:835-43. [PMID: 21644828 DOI: 10.4155/fmc.11.38] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
143 Sabatier R, Charafe-Jauffret E, Pierga JY, Curé H, Lambaudie E, Genre D, Houvenaeghel G, Viens P, Ginestier C, Bertucci F, Sfumato P, Extra JM, Gonçalves A. Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. J Clin Med 2019;8:E612. [PMID: 31064127 DOI: 10.3390/jcm8050612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, Vici P, Bianco V, Tomao F. Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget 2017;8:12389-405. [PMID: 27852039 DOI: 10.18632/oncotarget.13310] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 13.5] [Reference Citation Analysis]
145 Gadag S, Sinha S, Nayak Y, Garg S, Nayak UY. Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer. Pharmaceutics 2020;12:E524. [PMID: 32521684 DOI: 10.3390/pharmaceutics12060524] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
146 Sato S, Kurishima K, Miyazaki K, Kodama T, Ishikawa H, Kagohashi K, Tamura T, Homma S, Satoh H, Hizawa N. Efficacy of tyrosine kinase inhibitors in non-small-cell lung cancer patients undergoing dose reduction and those with a low body surface area. Mol Clin Oncol 2014;2:604-8. [PMID: 24940504 DOI: 10.3892/mco.2014.281] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
147 Mezi S, Botticelli A, Pomati G, Cerbelli B, Scagnoli S, Amirhassankhani S, d'Amati G, Marchetti P. Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:1080. [PMID: 33802438 DOI: 10.3390/cancers13051080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
148 Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: preclinical research and clinical development. Onco Targets Ther. 2014;7:1997-2006. [PMID: 25378934 DOI: 10.2147/ott.s61132] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
149 Velasco R, Bruna J. Taxane-Induced Peripheral Neurotoxicity. Toxics 2015;3:152-69. [PMID: 29056655 DOI: 10.3390/toxics3020152] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
150 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
151 Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW Jr. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 2018;36:2621-9. [PMID: 30040523 DOI: 10.1200/JCO.2018.79.2028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 8.7] [Reference Citation Analysis]
152 Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf 2012;3:59-69. [PMID: 25083226 DOI: 10.1177/2042098611430109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis 2019;22:15-36. [PMID: 30168025 DOI: 10.1007/s10456-018-9645-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 16.7] [Reference Citation Analysis]
154 Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol 2015;75:659-70. [PMID: 25596818 DOI: 10.1007/s00280-014-2607-5] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
155 Marmé F, Schneeweiss A. Targeted Therapies in Triple-Negative Breast Cancer. Breast Care (Basel) 2015;10:159-66. [PMID: 26557820 DOI: 10.1159/000433622] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
156 Zhu W, Kato Y, Artemov D. Heterogeneity of tumor vasculature and antiangiogenic intervention: insights from MR angiography and DCE-MRI. PLoS One 2014;9:e86583. [PMID: 24466160 DOI: 10.1371/journal.pone.0086583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
157 Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310-320. [PMID: 22276821 DOI: 10.1056/nejmoa1111097] [Cited by in Crossref: 322] [Cited by in F6Publishing: 149] [Article Influence: 35.8] [Reference Citation Analysis]
158 Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy. BMC Cancer 2012;12:482. [PMID: 23083011 DOI: 10.1186/1471-2407-12-482] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
159 Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011;13:R67. [PMID: 21699723 DOI: 10.1186/bcr2907] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 14.8] [Reference Citation Analysis]
160 Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. Med Oncol 2014;31:776. [PMID: 24271313 DOI: 10.1007/s12032-013-0776-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
161 Yamakawa M, Doh SJ, Santosa SM, Montana M, Qin EC, Kong H, Han KY, Yu C, Rosenblatt MI, Kazlauskas A, Chang JH, Azar DT. Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review. Med Res Rev 2018;38:1769-98. [PMID: 29528507 DOI: 10.1002/med.21496] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
162 Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM. Therapies for triple negative breast cancer. Expert Opin Pharmacother 2015;16:983-98. [PMID: 25881743 DOI: 10.1517/14656566.2015.1032246] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
163 Ahn KJ, Park J, Choi Y. Lymphovascular invasion as a negative prognostic factor for triple-negative breast cancer after surgery. Radiat Oncol J 2017;35:332-9. [PMID: 29232804 DOI: 10.3857/roj.2017.00416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
164 Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer 2019;19:140. [PMID: 30744578 DOI: 10.1186/s12885-019-5335-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
165 Di Mauro C, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Formisano L, De Falco S, Cicatiello V, Di Bonito M, Cantile M, Collina F, Chambery A, Veneziani BM, De Placido S, Bianco R. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer 2017;116:1425-35. [PMID: 28441382 DOI: 10.1038/bjc.2017.116] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
166 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
167 Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, Tong Z, Wang S, Li J, Wang Z. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820. [PMID: 25376790 DOI: 10.1186/1471-2407-14-820] [Cited by in Crossref: 99] [Cited by in F6Publishing: 109] [Article Influence: 14.1] [Reference Citation Analysis]
168 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 6.8] [Reference Citation Analysis]
169 Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G. Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med. 2014;2:123. [PMID: 25568876 DOI: 10.3978/j.issn.2305-5839.2014.08.14] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
170 Kruse V, Denys H, Van Den Broecke R, Van Belle S, Cocquyt V. The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most? Springerplus 2013;2:202. [PMID: 23710429 DOI: 10.1186/2193-1801-2-202] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
171 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
172 Redondo A, Ramos Vázquez M, Manso L, Gil Gil MJ, Garau Llinas I, García-Garre E, Rodríguez CA, Chacón JI, López-Vivanco G. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational "LORENA" study. Onco Targets Ther 2018;11:5845-52. [PMID: 30271167 DOI: 10.2147/OTT.S170303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
173 Ishizuna K, Ninomiya J, Kojima M, Kawashima M, Nozaki M, Yamagishi H, Ueda Y, Oya M. Paclitaxel-resistant advanced recurrent breast cancer: a case of partial response due to addition of bevacizumab to paclitaxel therapy: a case report. BMC Res Notes 2013;6:254. [PMID: 23830415 DOI: 10.1186/1756-0500-6-254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
174 Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205-2218. [PMID: 23669226 DOI: 10.1200/jco.2012.46.3653] [Cited by in Crossref: 645] [Cited by in F6Publishing: 347] [Article Influence: 80.6] [Reference Citation Analysis]
175 Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials. J Exp Clin Cancer Res 2011;30:54. [PMID: 21569417 DOI: 10.1186/1756-9966-30-54] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
176 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
177 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 463] [Article Influence: 45.0] [Reference Citation Analysis]
178 Gampenrieder SP, Westphal T, Greil R. Antiangiogenic therapy in breast cancer. Memo 2017;10:194-201. [PMID: 29250196 DOI: 10.1007/s12254-017-0362-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
179 Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013;123:3190-3200. [PMID: 23908119 DOI: 10.1172/jci70212] [Cited by in Crossref: 392] [Cited by in F6Publishing: 195] [Article Influence: 49.0] [Reference Citation Analysis]
180 Miles DW, de Haas SL, Dirix LY, Romieu G, Chan A, Pivot X, Tomczak P, Provencher L, Cortés J, Delmar PR. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer. Br J Cancer. 2013;108:1052-1060. [PMID: 23422754 DOI: 10.1038/bjc.2013.69] [Cited by in Crossref: 115] [Cited by in F6Publishing: 95] [Article Influence: 14.4] [Reference Citation Analysis]
181 Afranie-Sakyi JA, Klement GL. The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics. Cancer Lett 2015;357:1-7. [PMID: 25449430 DOI: 10.1016/j.canlet.2014.10.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
182 Vahdat LT, Layman R, Yardley DA, Gradishar W, Salkeni MA, Joy AA, Garcia AA, Ward P, Khatcheressian J, Sparano J, Rodriguez G, Tang S, Gao L, Dalal RP, Kauh J, Miller K. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. Oncologist 2017;22:245-54. [PMID: 28220020 DOI: 10.1634/theoncologist.2016-0265] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
183 Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. Br J Cancer 2014;111:2051-7. [PMID: 25268370 DOI: 10.1038/bjc.2014.504] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
184 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
185 Li H, Geng C, Zhao H, Jiang H, Song G, Zhang J, Liu Y, Gui X, Wang J, Li K, Tong Z, Zhao F, Yang J, Chen G, Liu Q, Liang X. Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis. Chin J Cancer Res 2021;33:243-55. [PMID: 34158743 DOI: 10.21147/j.issn.1000-9604.2021.02.11] [Reference Citation Analysis]
186 Cidon EU, Alonso P, Masters B. Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? Clin Med Insights Oncol 2016;10:41-55. [PMID: 27147901 DOI: 10.4137/CMO.S34542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
187 Guo S, Wong S. Cardiovascular toxicities from systemic breast cancer therapy. Front Oncol 2014;4:346. [PMID: 25538891 DOI: 10.3389/fonc.2014.00346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
188 Baselga J, Costa F, Gomez H, Hudis CA, Rapoport B, Roche H, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ. A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials. 2013;14:228. [PMID: 23876062 DOI: 10.1186/1745-6215-14-228] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
189 Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, Zhao R, Milstien S, Zhou H, Spiegel S. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012;72:726-735. [PMID: 22298596 DOI: 10.1158/0008-5472.can-11-2167] [Cited by in Crossref: 210] [Cited by in F6Publishing: 146] [Article Influence: 23.3] [Reference Citation Analysis]
190 Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab treatment for advanced breast cancer. Oncologist 2011;16:1684-97. [PMID: 21976315 DOI: 10.1634/theoncologist.2011-0113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
191 Chen X, Zheng Z, Chen L, Zheng H. MAPK, NFκB, and VEGF signaling pathways regulate breast cancer liver metastasis. Oncotarget 2017;8:101452-60. [PMID: 29254177 DOI: 10.18632/oncotarget.20843] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
192 Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S. Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J 2012;2:e67. [PMID: 22829969 DOI: 10.1038/bcj.2012.12] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
193 Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci Rep 2016;6:36694. [PMID: 27841282 DOI: 10.1038/srep36694] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
194 Cao L, Yao GY, Liu MF, Chen LJ, Hu XL, Ye CS. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials. PLoS One. 2015;10:e0145442. [PMID: 26717149 DOI: 10.1371/journal.pone.0145442] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
195 Lindholm EM, Kristian A, Nalwoga H, Krüger K, Nygård S, Akslen LA, Mælandsmo GM, Engebraaten O. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol Oncol 2012;6:418-27. [PMID: 22521242 DOI: 10.1016/j.molonc.2012.03.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
196 Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 2012;109:17561-6. [PMID: 23045683 DOI: 10.1073/pnas.1215397109] [Cited by in Crossref: 487] [Cited by in F6Publishing: 442] [Article Influence: 54.1] [Reference Citation Analysis]
197 Sunshine SB, Dallabrida SM, Durand E, Ismail NS, Bazinet L, Birsner AE, Sohn R, Ikeda S, Pu WT, Kulke MH, Javaherian K, Zurakowski D, Folkman JM, Rupnick M. Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition. Proc Natl Acad Sci U S A 2012;109:11306-11. [PMID: 22733742 DOI: 10.1073/pnas.1203275109] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
198 Chowdhury R, Ganeshan B, Irshad S, Lawler K, Eisenblätter M, Milewicz H, Rodriguez-Justo M, Miles K, Ellis P, Groves A, Punwani S, Ng T. The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. Br J Radiol 2014;87:20140065. [PMID: 24597512 DOI: 10.1259/bjr.20140065] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
199 Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Soy and breast cancer: focus on angiogenesis. Int J Mol Sci 2015;16:11728-49. [PMID: 26006245 DOI: 10.3390/ijms160511728] [Cited by in Crossref: 78] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
200 Chen Z, Xu S, Xu W, Huang J, Zhang GU, Lei L, Shao X, Wang X. Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance. Oncol Lett 2015;10:723-9. [PMID: 26622560 DOI: 10.3892/ol.2015.3348] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
201 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
202 Danni L, Lingyun Z, Jian W, Hongfei Y, Lu X, Peng Y, Xiujuan Q, Yunpeng L, Yuee T. Significant response to apatinib monotherapy in heavily pretreated advanced HER2-positive breast cancer: a case report and literature review. Cancer Biol Ther 2020;21:590-6. [PMID: 32233990 DOI: 10.1080/15384047.2020.1743159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
203 Owen LA, Uehara H, Cahoon J, Huang W, Simonis J, Ambati BK. Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One. 2012;7:e33576. [PMID: 22438952 DOI: 10.1371/journal.pone.0033576] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
204 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
205 Acar O, Esen T, Lack NA. New therapeutics to treat castrate-resistant prostate cancer. ScientificWorldJournal 2013;2013:379641. [PMID: 23781155 DOI: 10.1155/2013/379641] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
206 Torii M, Fukui T, Inoue M, Kanao S, Umetani K, Shirai M, Inagaki T, Tsuchimochi H, Pearson JT, Toi M. Analysis of the microvascular morphology and hemodynamics of breast cancer in mice using SPring-8 synchrotron radiation microangiography. J Synchrotron Radiat 2017;24:1039-47. [PMID: 28862627 DOI: 10.1107/S1600577517008372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
207 Livi L, Bonomo P, Meattini I, Simontacchi G, Greto D, Desideri I, Meacci F, Scotti V, Cecchini S, Nori J, Sanchez LJ, Orzalesi L, Paiar F, Biti G. Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience. Med Oncol 2013;30:434. [PMID: 23283649 DOI: 10.1007/s12032-012-0434-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
208 Petrelli F, Barni S. Bevacizumab in advanced breast cancer: an opportunity as second-line therapy? Med Oncol 2012;29:1-4. [PMID: 21161443 DOI: 10.1007/s12032-010-9773-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
209 Chau CH, Figg WD. Angiogenesis inhibitors increase tumor stem cells. Cancer Biol Ther 2012;13:586-7. [PMID: 22441817 DOI: 10.4161/cbt.19852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
210 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 406] [Cited by in F6Publishing: 348] [Article Influence: 81.2] [Reference Citation Analysis]
211 Oguntade AS, Al-Amodi F, Alrumayh A, Alobaida M, Bwalya M. Anti-angiogenesis in cancer therapeutics: the magic bullet. J Egypt Natl Canc Inst 2021;33:15. [PMID: 34212275 DOI: 10.1186/s43046-021-00072-6] [Reference Citation Analysis]
212 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 415] [Cited by in F6Publishing: 353] [Article Influence: 59.3] [Reference Citation Analysis]
213 Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res 2013;19:291-303. [PMID: 23136197 DOI: 10.1158/1078-0432.CCR-12-1611] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
214 Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit-risk assessment of bevacizumab in the treatment of breast cancer. Drug Saf 2012;35:15-25. [PMID: 22136182 DOI: 10.2165/11595910-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
215 Lindholm EM, Ragle Aure M, Haugen MH, Kleivi Sahlberg K, Kristensen VN, Nebdal D, Børresen-Dale AL, Lingjaerde OC, Engebraaten O. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer. Mol Oncol 2019;13:2278-96. [PMID: 31402562 DOI: 10.1002/1878-0261.12561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
216 Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Clin Cancer Res 2013;19:1281-9. [PMID: 23340303 DOI: 10.1158/1078-0432.CCR-12-3029] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
217 Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? Int J Mol Sci 2017;18:E85. [PMID: 28054957 DOI: 10.3390/ijms18010085] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
218 Tan QX, Qin QH, Lian B, Yang WP, Wei CY. Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials. Exp Ther Med 2014;7:1420-6. [PMID: 24940450 DOI: 10.3892/etm.2014.1603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
219 Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist 2013;18:273-80. [PMID: 23485622 DOI: 10.1634/theoncologist.2012-0339] [Cited by in Crossref: 74] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
220 Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Sci Rep 2021;11:3388. [PMID: 33564016 DOI: 10.1038/s41598-021-81914-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2012;23:331-7. [PMID: 21821545 DOI: 10.1093/annonc/mdr344] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
222 Cannita K, Paradisi S, Cocciolone V, Bafile A, Rinaldi L, Irelli A, Lanfiuti Baldi P, Zugaro L, Manetta R, Alesse E, Ricevuto E, Ficorella C. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. Cancer Med 2016;5:2232-9. [PMID: 27416882 DOI: 10.1002/cam4.803] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
223 Bakr NM, Mahmoud MS, Nabil R, Boushnak H, Swellam M. Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes. J Genet Eng Biotechnol 2021;19:84. [PMID: 34089425 DOI: 10.1186/s43141-021-00174-7] [Reference Citation Analysis]
224 Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res 2012;14:209. [PMID: 22713170 DOI: 10.1186/bcr3142] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
225 Sharma P. Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist 2016;21:1050-62. [PMID: 27401886 DOI: 10.1634/theoncologist.2016-0067] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 17.4] [Reference Citation Analysis]
226 Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, Fasola G, Puglisi F. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist 2014;19:608-15. [PMID: 24794159 DOI: 10.1634/theoncologist.2014-0002] [Cited by in Crossref: 108] [Cited by in F6Publishing: 100] [Article Influence: 15.4] [Reference Citation Analysis]
227 Yonucu S, Yιlmaz D, Phipps C, Unlu MB, Kohandel M. Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy. PLoS Comput Biol 2017;13:e1005724. [PMID: 28922358 DOI: 10.1371/journal.pcbi.1005724] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
228 Kirtane AR, Kalscheuer SM, Panyam J. Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. Adv Drug Deliv Rev 2013;65:1731-47. [PMID: 24036273 DOI: 10.1016/j.addr.2013.09.001] [Cited by in Crossref: 163] [Cited by in F6Publishing: 144] [Article Influence: 20.4] [Reference Citation Analysis]
229 Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther 2012;91:15-7. [PMID: 22179625 DOI: 10.1038/clpt.2011.288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
230 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
231 Hu Y, Ran M, Wang B, Lin Y, Cheng Y, Zheng S. Co-Delivery of Docetaxel and Curcumin via Nanomicelles for Enhancing Anti-Ovarian Cancer Treatment. Int J Nanomedicine 2020;15:9703-15. [PMID: 33299312 DOI: 10.2147/IJN.S274083] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
232 Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011;2011:284584. [PMID: 21760703 DOI: 10.1155/2011/284584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
233 Ishiguro H, Takashima S, Yoshimura K, Yano I, Yamamoto T, Niimi M, Yamashiro H, Ueno T, Takeuchi M, Sugie T, Yanagihara K, Toi M, Fukushima M. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. Support Care Cancer 2012;20:2017-24. [PMID: 22086405 DOI: 10.1007/s00520-011-1308-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
234 Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016;374:738-748. [PMID: 26933849 DOI: 10.1056/nejmoa1505067] [Cited by in Crossref: 209] [Cited by in F6Publishing: 75] [Article Influence: 41.8] [Reference Citation Analysis]
235 Iwai T, Harada Y, Saeki H, Oki E, Maehara Y, Yonemitsu Y. Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells. Oncotarget 2018;9:17620-30. [PMID: 29707135 DOI: 10.18632/oncotarget.24811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
236 Lohmann AE, Chia S. Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? Curr Treat Options Oncol 2012;13:249-62. [PMID: 22350496 DOI: 10.1007/s11864-012-0181-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
237 Dos Anjos Pultz B, da Luz FA, de Faria PR, Oliveira AP, de Araújo RA, Silva MJ. Far beyond the usual biomarkers in breast cancer: a review. J Cancer 2014;5:559-71. [PMID: 25057307 DOI: 10.7150/jca.8925] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
238 Bourdeanu L, Luu T. Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice. J Adv Pract Oncol 2014;5:246-60. [PMID: 26110069 DOI: 10.6004/jadpro.2014.5.4.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
239 Sa-Nguanraksa D, O-Charoenrat P. The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci 2012;13:14845-64. [PMID: 23203097 DOI: 10.3390/ijms131114845] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
240 McDowell SAC, Quail DF. Immunological Regulation of Vascular Inflammation During Cancer Metastasis. Front Immunol 2019;10:1984. [PMID: 31497019 DOI: 10.3389/fimmu.2019.01984] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
241 Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90. [PMID: 22525710 DOI: 10.1038/nrclinonc.2012.64] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 12.8] [Reference Citation Analysis]
242 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
243 Goldfarb SB, Hudis C, Dickler MN. Bevacizumab in metastatic breast cancer: when may it be used? Ther Adv Med Oncol 2011;3:85-93. [PMID: 21789158 DOI: 10.1177/1758834010397627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
244 Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol 2017;5:101. [PMID: 29270405 DOI: 10.3389/fcell.2017.00101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
245 Gogineni K, DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res 2012;14:205. [PMID: 22429313 DOI: 10.1186/bcr3064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
246 Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C. Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis. Clin Transl Oncol 2016;18:40-6. [PMID: 26141413 DOI: 10.1007/s12094-015-1334-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
247 Zhang H, Huang Z, Zou X, Liu T. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget 2016;7:82473-81. [PMID: 27756883 DOI: 10.18632/oncotarget.12666] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 9.3] [Reference Citation Analysis]
248 Chalasani P, Marron M, Roe D, Clarke K, Iannone M, Livingston RB, Shan JS, Stopeck AT. A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer. Cancer Med 2015;4:1051-9. [PMID: 25826750 DOI: 10.1002/cam4.447] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
249 Spurrell EL, Lockley M. Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience 2014;8:441. [PMID: 25075215 DOI: 10.3332/ecancer.2014.441] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
250 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
251 Mohan A, Ponnusankar S. Newer therapies for the treatment of metastatic breast cancer: a clinical update. Indian J Pharm Sci 2013;75:251-61. [PMID: 24082340 DOI: 10.4103/0250-474X.117396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.9] [Reference Citation Analysis]
252 Cortes J, Vidal M. Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Res Treat 2012;133:821-30. [PMID: 22113255 DOI: 10.1007/s10549-011-1875-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
253 Rubinstein L, Leblanc M, Smith MA. More randomization in phase II trials: necessary but not sufficient. J Natl Cancer Inst 2011;103:1075-7. [PMID: 21709273 DOI: 10.1093/jnci/djr238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
254 Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control 2012;19:309-16. [PMID: 23037498 DOI: 10.1177/107327481201900407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
255 Madu CO, Wang S, Madu CO, Lu Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J Cancer 2020;11:4474-94. [PMID: 32489466 DOI: 10.7150/jca.44313] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
256 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 110] [Article Influence: 14.7] [Reference Citation Analysis]
257 Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561-574. [PMID: 20808300 DOI: 10.1038/nrclinonc.2010.122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
258 Xu B, Hu X, Jiang Z, Li H, Chen J, Cui S, Li Q, Liao N, Liu D, Liu J, Lu J, Shen K, Sun T, Teng Y, Tong Z, Wang S, Wang X, Wang X, Wang Y, Wu J, Yuan P, Zhang P, Zhang Q, Zheng H, Pang D, Ren G, Shao Z, Shen Z, Song E, Song S. National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Ann Transl Med 2015;3:242. [PMID: 26605288 DOI: 10.3978/j.issn.2305-5839.2015.09.47] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
259 Meadows KL, Rushing C, Honeycutt W, Latta K, Howard L, Arrowood CA, Niedzwiecki D, Hurwitz HI. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study. Support Care Cancer 2015;23:1311-9. [PMID: 25341548 DOI: 10.1007/s00520-014-2465-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]